{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T13:40:42Z","timestamp":1767188442777,"version":"3.48.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"National Major Scientific and Technological Special Project for \u201cSignificant New Drugs Development\u201d","award":["2018ZX09734-001"],"award-info":[{"award-number":["2018ZX09734-001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s40268-025-00532-7","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T20:01:35Z","timestamp":1765224095000},"page":"377-386","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Multiple-Dose Up-Titration Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Omecamtiv Mecarbil in Healthy Chinese Subjects"],"prefix":"10.1007","volume":"25","author":[{"given":"Xuening","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongrong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanjing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengjie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5784-076X","authenticated-orcid":false,"given":"Lei","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,8]]},"reference":[{"issue":"1","key":"532_CR1","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1517\/13543784.2016.1123248","volume":"25","author":"LC Liu","year":"2016","unstructured":"Liu LC, Dorhout B, van der Meer P, Teerlink JR, Voors AA. Omecamtiv mecarbil: a new cardiac myosin activator for the treatment of heart failure. Expert Opin Investig Drugs. 2016;25(1):117\u201327. https:\/\/doi.org\/10.1517\/13543784.2016.1123248.","journal-title":"Expert Opin Investig Drugs"},{"issue":"2","key":"532_CR2","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/ejhf.2763","volume":"25","author":"KF Docherty","year":"2023","unstructured":"Docherty KF, McMurray JJV, Claggett BL, Miao ZM, Adams KF, Arias-Mendoza A, et al. Efficacy of omecamtiv mecarbil in heart failure with reduced ejection fraction according to N-terminal pro-B-type natriuretic peptide level: insights from the GALACTIC-HF trial. Eur J Heart Fail. 2023;25(2):248\u201359. https:\/\/doi.org\/10.1002\/ejhf.2763.","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"532_CR3","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1097\/FJC.0000000000000929","volume":"77","author":"TD Bernier","year":"2021","unstructured":"Bernier TD, Buckley LF. Cardiac myosin activation for the treatment of systolic heart failure. J Cardiovasc Pharmacol. 2021;77(1):4\u201310. https:\/\/doi.org\/10.1097\/FJC.0000000000000929.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"10062","key":"532_CR4","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1016\/s0140-6736(16)32049-9","volume":"388","author":"JR Teerlink","year":"2016","unstructured":"Teerlink JR, Felker GM, McMurray JJV, Solomon SD, Adams KF, Cleland JGF, et al. Chronic oral study of myosin activation to increase contractility in heart failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. Lancet. 2016;388(10062):2895\u2013903. https:\/\/doi.org\/10.1016\/s0140-6736(16)32049-9.","journal-title":"Lancet"},{"issue":"14","key":"532_CR5","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1056\/NEJMoa2025797","volume":"384","author":"JR Teerlink","year":"2021","unstructured":"Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, et al. Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure. N Engl J Med. 2021;384(14):105\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2025797.","journal-title":"N Engl J Med"},{"issue":"8","key":"532_CR6","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.jacc.2025.06.036","volume":"86","author":"S Kaul","year":"2025","unstructured":"Kaul S. Evidentiary landscape of heart failure therapies, regulatory decisions, and translation into guidelines. J Am Coll Cardiol. 2025;86(8):610\u201324. https:\/\/doi.org\/10.1016\/j.jacc.2025.06.036.","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"532_CR7","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/S0140-6736(11)61126-4","volume":"378","author":"JG Cleland","year":"2011","unstructured":"Cleland JG, Teerlink JR, Senior R, Nifontov EM, Mc Murray JJ, Lang CC, et al. The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. Lancet. 2011;378(20):676\u201383. https:\/\/doi.org\/10.1016\/S0140-6736(11)61126-4.","journal-title":"Lancet"},{"issue":"9792","key":"532_CR8","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/S0140-6736(11)61219-1","volume":"378","author":"JR Teerlink","year":"2011","unstructured":"Teerlink JR, Clarke CP, Saikali KG, Lee JH, Chen MM, Escandon RD, et al. Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study. Lancet. 2011;378(9792):667\u201375. https:\/\/doi.org\/10.1016\/S0140-6736(11)61219-1.","journal-title":"Lancet"},{"issue":"6","key":"532_CR9","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s13318-021-00711-2","volume":"46","author":"A Trivedi","year":"2021","unstructured":"Trivedi A, Malik FI, Mackowski M, Hutton S, Aoki M, Abbasi S, et al. Pharmacokinetics, tolerability, and safety of single and multiple omecamtiv mecarbil doses in healthy Japanese and Caucasian subjects. Eur J Drug Metab Pharmacokinet. 2021;46(6):759\u201370. https:\/\/doi.org\/10.1007\/s13318-021-00711-2.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"4","key":"532_CR10","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1097\/FJC.0000000000001207","volume":"79","author":"P-W Chen","year":"2022","unstructured":"Chen P-W, Trivedi A, Lee E, Dutta S, Ahamadi M. Population pharmacokinetic properties of omecamtiv mecarbil in healthy subjects and patients with heart failure with reduced ejection fraction. J Cardiovasc Pharmacol. 2022;79(4):539\u201348. https:\/\/doi.org\/10.1097\/FJC.0000000000001207.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"3","key":"532_CR11","doi-asserted-by":"publisher","first-page":"217","DOI":"10.5414\/CP202458","volume":"54","author":"R Palaparthy","year":"2016","unstructured":"Palaparthy R, Banfield C, Alvarez P, Yan L, Smith B, Johnson J, et al. Relative bioavailability, food effect, and safety of the single-dose pharmacokinetics of omecamtiv mecarbil following administration of different modified-release formulations in healthy subjects. Int J Clin Pharmacol Ther. 2016;54(3):217\u201327. https:\/\/doi.org\/10.5414\/CP202458.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"11","key":"532_CR12","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1002\/psp4.12354","volume":"7","author":"JD Clements","year":"2018","unstructured":"Clements JD, Perez Ruixo JJ, Gibbs JP, Doshi S, Perez Ruixo C, Melhem M. Receiver operating characteristic analysis and clinical trial simulation to inform dose titration decisions. CPT Pharmacometrics Syst Pharmacol. 2018;7(11):771\u20139. https:\/\/doi.org\/10.1002\/psp4.12354.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"1","key":"532_CR13","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.mpaic.2021.10.014","volume":"23","author":"DV Eusuf","year":"2022","unstructured":"Eusuf DV, Thomas E. Pharmacokinetic variation. Anaesth Intensive Care Med. 2022;23(1):50\u20133. https:\/\/doi.org\/10.1016\/j.mpaic.2021.10.014.","journal-title":"Anaesth Intensive Care Med"},{"issue":"7","key":"532_CR14","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/bdd.2293","volume":"42","author":"A Trivedi","year":"2021","unstructured":"Trivedi A, Oberoi RK, Mackowski M, Jafarinasabian P, Zhang H, Flach S, et al. Switchability and minimal effect of food on pharmacokinetics of modified release tablet strengths of omecamtiv mecarbil, a cardiac myosin activator. Biopharm Drug Dispos. 2021;42(7):319\u201328. https:\/\/doi.org\/10.1002\/bdd.2293.","journal-title":"Biopharm Drug Dispos"},{"issue":"8","key":"532_CR15","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s40262-021-01014-0","volume":"60","author":"A Trivedi","year":"2021","unstructured":"Trivedi A, Oberoi RK, Jafarinasabian P, Zhang H, Flach S, Abbasi S, et al. Effect of varying degrees of renal impairment on the pharmacokinetics of omecamtiv mecarbil. Clin Pharmacokinet. 2021;60(8):1041\u20138. https:\/\/doi.org\/10.1007\/s40262-021-01014-0.","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"532_CR16","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1002\/cpdd.969","volume":"10","author":"A Trivedi","year":"2021","unstructured":"Trivedi A, Oberoi RK, Mackowski M, Jafarinasabian P, Zhang H, Flach S, et al. Effect of varying degrees of hepatic impairment on the pharmacokinetics of omecamtiv mecarbil. Clin Pharmacol Drug Dev. 2021;10(12):1442\u201351. https:\/\/doi.org\/10.1002\/cpdd.969.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"7","key":"532_CR17","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s40261-021-01051-4","volume":"41","author":"A Trivedi","year":"2021","unstructured":"Trivedi A, Oberoi RK, Jafarinasabian P, Zhang H, Spring M, Flach S, et al. Effect of omecamtiv mecarbil on the pharmacokinetics of metformin, a probe substrate for MATE1\/MATE2-K, in healthy subjects. Clin Drug Investig. 2021;41(7):647\u201352. https:\/\/doi.org\/10.1007\/s40261-021-01051-4.","journal-title":"Clin Drug Investig"},{"issue":"3","key":"532_CR18","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1002\/cpdd.1028","volume":"11","author":"A Trivedi","year":"2022","unstructured":"Trivedi A, Sohn W, Hsu CP, Jafarinasabian P, Zhang H, Hutton S, et al. Pharmacokinetic drug-drug interaction study of omecamtiv mecarbil with amiodarone and digoxin in healthy subjects. Clin Pharmacol Drug Dev. 2022;11(3):388\u201396. https:\/\/doi.org\/10.1002\/cpdd.1028.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"1","key":"532_CR19","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/cpdd.997","volume":"11","author":"A Trivedi","year":"2022","unstructured":"Trivedi A, Sohn W, Jafarinasabian P, Zhang H, Terminello B, Flach S, et al. Pharmacokinetic drug-drug interaction study of omecamtiv mecarbil with omeprazole, a proton pump inhibitor, in healthy subjects. Clin Pharmacol Drug Dev. 2022;11(1):129\u201333. https:\/\/doi.org\/10.1002\/cpdd.997.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"2","key":"532_CR20","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/cpdd.987","volume":"11","author":"A Trivedi","year":"2022","unstructured":"Trivedi A, Malik FI, Jafarinasabian P, Zhang H, Flach S, Abbasi S, et al. Pharmacokinetic evaluation of the CYP3A4 and CYP2D6 drug-drug interaction and CYP3A4 induction potential of omecamtiv mecarbil: two open-label studies in healthy subjects. Clin Pharmacol Drug Dev. 2022;11(2):185\u201393. https:\/\/doi.org\/10.1002\/cpdd.987.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"11","key":"532_CR21","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1002\/ejhf.2015","volume":"22","author":"JR Teerlink","year":"2020","unstructured":"Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, et al. Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials. Eur J Heart Fail. 2020;22(11):2160\u201371. https:\/\/doi.org\/10.1002\/ejhf.2015.","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"532_CR22","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.jchf.2019.12.001","volume":"8","author":"JR Teerlink","year":"2020","unstructured":"Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, et al. Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: rationale and design of GALACTIC-HF. JACC Heart Fail. 2020;8(4):329\u201340. https:\/\/doi.org\/10.1016\/j.jchf.2019.12.001.","journal-title":"JACC Heart Fail"},{"issue":"8","key":"532_CR23","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1124\/dmd.121.000444","volume":"49","author":"A Trivedi","year":"2021","unstructured":"Trivedi A, Wahlstrom J, Mackowski M, Dutta S, Lee E. Pharmacokinetics, disposition, and biotransformation of [(14)C]omecamtiv mecarbil in healthy male subjects after a single intravenous or oral dose. Drug Metab Dispos. 2021;49(8):619\u201328. https:\/\/doi.org\/10.1124\/dmd.121.000444.","journal-title":"Drug Metab Dispos"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-025-00532-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40268-025-00532-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-025-00532-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T13:36:09Z","timestamp":1767188169000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40268-025-00532-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["532"],"URL":"https:\/\/doi.org\/10.1007\/s40268-025-00532-7","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"type":"print","value":"1174-5886"},{"type":"electronic","value":"1179-6901"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"7 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Xuening Li, Hui Li, Hongrong Xu , Fei Yuan, Hanjing Chen, Chao Liu, Mengjie Yang, Jing Li, and Lei Sheng have no conflicts of interest that are directly relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was conducted in accordance with regulations and guidelines established by the International Council for Harmonisation Good Clinical Practice and the National Medical Products Administration. The study was registered at the Chinese Clinical Trial Registry (Registration no. CTR20170957; date of registration: 3 April, 2019). Prior to study initiation, the study protocol was approval by an Independent Ethics Committee at Zhongshan Hospital, Fudan University (approval number: 2019-019).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"All participants provided written informed consent before the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"All datasets generated in this study are available from the corresponding author upon reasonable request for research purposes.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"LS contributed to the analysis and interpretation of the data and writing of the initial draft of the paper. XL and HL were involved in the drafting process of the paper. HX, FY, HC, CL, MY, and JL performed the clinical trial. All authors have read and approved the final version.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}